美托洛尔在维持性血液透析患者心律失常的应用

摘要

ObjectiveTo investigate application effect by metoprolol for arrhythmia in maintenance hemodialysis (MHD) patients, and its influence on MHD.MethodsA total of 26 patients with arrhythmia in MHD were randomly divided into treatment group (14 cases) and control group (12 cases). The treatment group received metoprolol by oral administration before hemodialysis, and the control group received no treatment before hemodialysis. Comparison was made on arrhythmia times and types in MHD between the two groups.Results There were totally 1006 times of MHD in 14 cases of the treatment group, along with 19 times of arrhythmia and incidence as 2%. 12 cases of the control group had 866 times of MHD and 219 times of arrhythmia, with incidence as 25%. The treatment group had lower incidence of arrhythmia than the control group, and their difference had statistical significance (χ2=229.63,P<0.05).ConclusionImplement of metoprolol provides creditable effect in preventing and treating arrhythmia in MHD patients, and this method is worth promoting.%目的：探讨美托洛尔在维持性血液透析(MHD)患者心律失常的应用疗效及对MHD的影响。方法26例MHD中发生心律失常患者,随机分为治疗组(14例)和对照组(12例),治疗组透析前口服美托洛尔片,对照组透析前未予特殊处理。比较两组患者MHD过程中发生心律失常的次数和种类。结果治疗组14例患者共MHD 1006次,发生心律失常19次,发生率为2%；对照组12例患者共MHD 866次,发生心律失常219次,发生率为25%；治疗组心律失常发生率低于对照组,差异具有统计学意义(χ2=229.63,P<0.05)。结论美托洛尔用于MHD患者心律失常的预防和治疗效果可靠,值得推广。